{
    "clinical_study": {
        "@rank": "141302", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: Placebo (PL)", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Part 1: Single Ascending Doses (SAD) of RO6836191", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Part 2: RO6836191: LS followed by NS diet", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 2: PL: NS followed by LS diet", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Part 2: RO6836191: NS followed by LS diet", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This single-center, randomized, placebo-controlled, double-blind study will assess the\n      safety, pharmacokinetics and pharmacodynamics of RO6836191 in healthy male volunteers in two\n      parts. Part 1 will assess the safety of oral single ascending doses of RO6836191 compared to\n      placebo in fasted volunteers. In Part 2, participants will be given two single oral doses of\n      RO6836191 or placebo under low or normal-salt diet conditions. A subset of these\n      participants will subsequently receive a single IV dose of RO6836191 for further analysis."
        }, 
        "brief_title": "A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atherosclerosis", 
        "condition_browse": {
            "mesh_term": "Atherosclerosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteers, aged 18 to 45 years old.\n\n          -  No active or chronic disease following a detailed medical and surgical history and\n             complete physical examination.\n\n          -  A BMI between 18 to 30 kg/m2 inclusive.\n\n          -  Use of a highly effective form of birth control for the duration of the study and\n             until 90 days after the last dose.\n\n        Exclusion Criteria:\n\n          -  Any clinically relevant current or history of conditions or illnesses.\n\n          -  Clinically significant symptoms of infection within 5 days of the first dosing day or\n             a history of recurrent infections.\n\n          -  Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse.\n\n          -  Smokers unable or unwilling to restrict to 5 cigarettes daily during the study and to\n             not smoke during the stay at the clinic.\n\n          -  Any cardiac abnormalities.\n\n          -  Blood donation over 450 mL within three months prior to screening.\n\n          -  Participation in an investigational drug or device study within 3 months prior to\n             dosing.\n\n          -  Corticosteroid use within 3 months prior to dosing."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995383", 
            "org_study_id": "WP28586"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part 1: Single Ascending Doses (SAD) of RO6836191", 
                "description": "Orally administered, single ascending doses", 
                "intervention_name": "RO6836191", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 1: Placebo (PL)", 
                "description": "Single oral administrations", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 2: RO6836191: LS followed by NS diet", 
                    "Part 2: RO6836191: NS followed by LS diet"
                ], 
                "description": "2 single oral doses", 
                "intervention_name": "RO6836191", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 2: PL: NS followed by LS diet", 
                    "Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet"
                ], 
                "description": "2 single oral administrations", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 2: RO6836191: LS followed by NS diet", 
                    "Part 2: PL: NS followed by LS diet", 
                    "Part 2: RO6836191: NS followed by LS diet", 
                    "Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet"
                ], 
                "description": "Intravenous administration", 
                "intervention_name": "RO6836191", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 2: RO6836191: LS followed by NS diet", 
                    "Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet"
                ], 
                "description": "LS diet period followed by NS diet period", 
                "intervention_name": "LS followed by NS diet condition", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Part 2: PL: NS followed by LS diet", 
                    "Part 2: RO6836191: NS followed by LS diet"
                ], 
                "description": "NS diet period followed by LS diet period", 
                "intervention_name": "NS followed by LS diet condition", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands", 
                    "zip": "9713 GZ"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Single Oral Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Subjects Including a Single Intravenous Microdose of RO6836191", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: WP28586 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "The Netherlands: De Centrale Commissie Mensgebonden Onderzoek"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Parts 1: Incidence of adverse events (AE)", 
                "safety_issue": "No", 
                "time_frame": "Until Day 21"
            }, 
            {
                "measure": "Part 2: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 35"
            }, 
            {
                "measure": "Part 2: Plasma aldosterone levels", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 days after drug administration"
            }, 
            {
                "measure": "Part 2: Urine aldosterone levels", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 days after drug administration"
            }, 
            {
                "measure": "Part 1: Plasma aldosterone levels", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 5"
            }, 
            {
                "measure": "Part 1: Urine aldosterone levels", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 3"
            }, 
            {
                "measure": "Part 2: Incidence of AEs", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995383"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Part 2: Volume of distribution after intravenous administration", 
            "safety_issue": "No", 
            "time_frame": "Days 28-37"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}